TrialThe Lancet. Oncology2021

Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.

Assuntina G Sacco et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.